InvestorsHub Logo
Followers 6
Posts 2155
Boards Moderated 0
Alias Born 11/26/2014

Re: doogdilinger post# 33789

Friday, 03/23/2018 10:36:51 AM

Friday, March 23, 2018 10:36:51 AM

Post# of 38634
Doog- Thanks! Here is the PODRAS statement in company operational update. Lets hope they get these tests done in 1H2018 like it says.

Intellectual Property Portfolio

PODRAS™ Technology

Intellipharmaceutics continues to make progress regarding its PODRAS™ delivery technology, recently obtaining three additional patents from the U.S. Patent and Trademark Office (U.S. Patent Nos. 9700515 and 9700516 in July 2017 and No. 9,801,939 in October 2017) also entitled "Compositions and Methods for Reducing Overdose" and covering aspects of the Company's PODRAS™ delivery technology. The Company is optimistic about the prospects of this technology, which deliberately regulates the bioavailability of active ingredients in both generic and non-generic medications in a way that reduces the opportunity for overdose and/or abuse. The Company is finalizing plans to initiate proof of concept trials in humans. The Company believes that the preclinical work on the technology to date has shown encouraging results, but human trials are required to show that the technology works as expected. The human studies for PODRAS™ are expected to take place in the first half of 2018. Based on the results of these studies, the Company will evaluate commercial opportunities for the technology including potential out-licensing as well as incorporation into products within our pipeline.